Nanvuranlat confers PFS gains in advanced, refractory biliary tract cancer
The investigational L-type amino acid transporter 1 inhibitor nanvuranlat has an acceptable safety profile and is associated with prolonged progression-free survival (PFS) in patients with advanced and refractory biliary tract cancer when used in later-line treatment settings, according to the results of a phase II study.
Nanvuranlat confers PFS gains in advanced, refractory biliary tract cancer
26 Sep 2024